Crescent Capital Consulting’s Chemours CC Stock Holding History

Crescent Capital Consulting’s Portfolio CC Stock Details CC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-18	Closed	-$1K	–	495
2021 Q1	$1K	Buy	+18	New	+$479	﹤0.01%	473

Other funds holding CC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Crescent Capital Consulting's CC Position: Q2 2021 in Review

Crescent Capital Consulting sold out of Chemours (CC) in Q2 2021, closing a stake of 18 shares — an estimated $1K sold.

Crescent Capital Consulting first reported a position in CC in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 449 funds tracked by Wall St. Rank hold CC as of Q2 2021.

Crescent Capital Consulting reported no remaining Chemours position as of Q2 2021 after selling out during the quarter.
Crescent Capital Consulting sold 18 Chemours shares in Q2 2021, an estimated $1K.
Crescent Capital Consulting first reported a position in Chemours in Q1 2021 and held it in 1 quarter.
Crescent Capital Consulting's Chemours position peaked at $1K in Q1 2021.
449 funds tracked by Wall St. Rank held Chemours as of Q2 2021.

Based on Crescent Capital Consulting's 13F filing for Q2 2021, filed 15 Jul 2021.